The UNION team and advisors account for more than 10 drug approvals.


Dr. Kim Domela Kjøller, Chief Executive Officer

Kim Domela Kjøller has been CEO of UNION since January 2021 and brings more than 20 years of experience from various senior executive positions in the pharmaceutical industry, of which the last 10 years were in dermatology.

Before Union, Kim was the Head of R&D at LEO Pharma. Kim also held senior positions in both Strategic Marketing, Medical Affairs, Global Development and as General Manager at Sanofi, Lundbeck, Sanofi Pasteur MSD. His past experience covers both corporate and affiliate positions.

Kim is an MD from Copenhagen University and has authored and co-authored over 35 scientific publications, and given presentations at both scientific and pharmaceutical marketing meetings globally.


Morten Boesen, Chief Financial Officer

Morten Boesen joined UNION in 2018 as Chief Financial Officer. Prior to UNION, Morten worked with EQT, the largest private equity fund in the Nordics, initially as an investment professional and subsequently as an executive director in the EQT-owned global retailer Flying Tiger Copenhagen, where he held responsibility for strategy, business development as well as global commercial and supply chain operations. Earlier in his career, Morten worked as a management consultant with McKinsey & Company, in the M&A advisory group of Nordea Bank and in the finance department of Novozymes, the world leader in industrial biotech.

Morten holds a M.Sc. in Finance and Accounting from Copenhagen Business School and studied at New York University’s Stern School of Business and Tsinghua University’s School of Economics and Management.


Dr. Rasmus Toft-Kehler, Chief Operating Officer

Rasmus Toft-Kehler is the Co-Founder and board member of multiple biotech and life-science companies. Before going into biotech, Rasmus worked in investment banks and in management consulting, and acted as board member of a family-owned company that was sold in 2005.

Rasmus is the inventor of over 5 patents issued and has published research in leading entrepreneurship and scientific journals such as Journal of Business Venturing and Nature Reviews Microbiology.

Rasmus holds a Ph.D. in entrepreneurship from Copenhagen Business School and executive education from Harvard Business School.
In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.


Dr. Morten Sommer, Chief Scientific Officer

Morten Sommer is the Co-Founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.Ds and Post-Doctorial researchers working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents/patent applications and author of scientific papers in journals such as Science, Cell and Nature. Morten was named among the Top 10 under 40 in Genetic Engineering and Biotechnology News list of biopharma research and business executives.

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.


Dr. Per Cantor, Chief Medical Officer

Per Cantor joined UNION as Chief Medical Officer in April 2021 and brings 30 years of experience from pharma companies in Europe, USA, and China. He spent 14 years at Ferring as SVP of Clinical & Non-clinical R&D, including two years in China to establish the Ferring Institute of Reproductive Medicine in Beijing. Prior to Ferring, he spent 15 years at Eli Lilly in both the Nordic countries and at the Lilly Laboratories in the US, leading major clinical development programs within endocrinology and Women’s Health.

His R&D experience covers multiple therapeutic areas from drug discovery, pre-clinical pharmacology and toxicology, clinical Phase I-IV, product launch, and Life Cycle Management. He is the author of 50+ scientific publications and holder of several patents within prostate cancer therapy.

Per obtained MD and DMSci degrees from the University of Copenhagen and a BACom from Copenhagen Business School.


Eckhard Niemeier, Chief Business Officer

Eckhard Niemeier is a highly-experienced deal maker in the life science sector, drawing on almost 20 years of experience in corporate development, corporate strategy and financial analysis and valuation.

Before joining UNION in June 2021, Eckhard was SVP, Head of Business Development and Portfolio Management at Pieris Pharmaceuticals (Nasdaq:PIRS), where he was responsible for all business and corporate development activities including establishing strategic partnerships with AstraZeneca, Roche/Genentech, Seagen and Servier. Prior to joining Pieris, Eckhard held senior business development positions at Gruenenthal Pharma, where he was responsible for international licensing activities across all stages of drug development, and MorphoSys AG, where he negotiated multiple product and technology licensing deals. Eckhard began his career at McKinsey & Company in their Healthcare Practice.

Eckhard holds a M.Sc. in Biotechnology and completed his thesis in Molecular Biology at Human Genome Sciences, now part of GSK


Dr. Günter Ditzinger, Chief Technology Officer

Günter Ditzinger, Ph.D. has more than 30 years of pharmaceutical innovation experience spanning early development to product launch at Sanofi and subsequently Novartis. Before joining UNION in 2020, Günter was Chief Technology Officer at Basilea Pharmaceutica, where he was responsible for pharmaceutical, chemical and analytical development as well as the commercial supply chain at the global level. Günter has played vital roles in the successful development and commercial launch of multiple marketed products: Toctino® in chronic hand eczema, Zevtera® in bacterial infections, and Cresemba® in systemic fungal Infections.

Günter is a Registered Pharmacist, and holds a Ph.D. in Pharmaceutical Technology from Goethe University in Frankfurt/Main, Germany.


Mads Jellingsø, Chief Commercial Officer

Mads Jellingsø has broad market access experience from Novo Nordisk A/S where he was part of building new functions for real world evidence generation and for innovative contracting. In these teams Mads was driving Novo Nordisk’s global efforts to initiate partnerships with payers and providers around evidence generation and developing new financial and outcomes-based approaches to secure access for products in hemophilia, diabetes and obesity. Prior to specializing in market access, Mads has worked within the off-shoring and legal affairs department at Novo Nordisk and also has experience in management consulting at McKinsey & Company and in banking at Nordea Markets.

Mads holds a M.Sc. in Economics from University of Copenhagen.


Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Lutz Wevelsiep, Ph.D. has more than 25 years’ experience in international regulatory affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. Lutz has prepared and managed interactions with all health authorities including the  FDA, EMA and EU national agencies.

Prior to UNION, Lutz spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes the successful European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®).

Lutz holds a Ph.D. and Postdoc in Chemistry from the Max-Planck Institute in Germany.


Dr. Philippe Andres, Medical Lead, Dermatology

Philippe Andres is a French national with over 20 years of experience as dermatologist in the pharma industry, most recently as a member of the executive team at Galderma/Nestlé Skin Health. He has a wealth of experience in encompassing early and late stage developments, scientific communication and medical affairs.

During his career, Philippe has been involved in developing and launching multiple approved products, including topicals calcitriol (Vectical®) and adapalene (Differin®), submitted more than 100 patents and has published numerous scientific papers.

Philippe is an M.D. and Board Certified Dermatologist from Nantes University, France.


Gina Fischer, Project Director

Gina Fischer joined Union Dec 2020, as Program Director for orismilast and brings more than 18 years of experience in the pharmaceutical industry within project, alliance, and portfolio management. Before UNION, Gina has led several joint developments - and cross-cultural teams in Nycomed as well as in LEO Pharma in various positions across the value chain, from R&D, commercial, manufacturing, and lifecycle management.
Her track record includes Global approvals of Tachosil®, Daivobet® gel in China, and Enstilar® in the US and EU.

Gina holds an M.Sc. in Chemistry from the University of Copenhagen.


Tanya Arp Regnersgaard, Project Director

Tanya Arp Regnersgaard joined UNION July 1, 2021, as Project Director for UNI911. Tanya brings more than 16 years of experience in the pharmaceutical and medical device industry.

Before joining UNION Tanya spend more than 11 years in LEO Pharma in various positions in both R&D and Commercial. She has extensive experience with portfolio and project management from early and late-stage development programs incl. life cycle management. The last 3 years Tanya was the Global Launch Lead, preparing for commercialization in US, EU & Japan, for the novel monoclonal antibody to treat Atopic Dermatitis which achieved EMA approval in June 2021.

Tanya holds a Bachelor of Science in Export Engineering from the Engineering College of Copenhagen.